ChAd63-MVA malaria vaccine

ChAd63-MVA malaria vaccine refers to a suite of viral-vectored vaccine candidates developed by the University of Oxford, utilizing a heterologous prime-boost immunization strategy. The regimen typically involves a primary dose of a chimpanzee adenovirus vector (ChAd63 or AdCh63) followed by a booster dose of a Modified Vaccinia Ankara (MVA) vector. These vectors are engineered to express specific Plasmodium falciparum antigens: Apical Membrane Antigen 1 (AMA1), Merozoite Surface Protein 1 (MSP1), and Multiple-Epitope Thrombospondin-Related Adhesion Protein (ME-TRAP). AMA1 and MSP1 are blood-stage antigens intended to limit parasite multiplication in erythrocytes, while ME-TRAP is a pre-erythrocytic antigen designed to induce cellular immunity against the liver stage of infection. This approach aims to elicit both high-titer antibodies and potent T-cell responses to provide comprehensive protection against malaria. These candidates have been evaluated in Phase I/IIa clinical trials using controlled human malaria infection (CHMI) models involving sporozoite challenge via mosquito bites.

Other names

sporozoite-University of Oxford-malariaOxford viral-vectored malaria vaccinesChAd63-MVA prime-boost malaria vaccineChAd-63-MVA prime-boost malaria vaccineChAd 63-MVA prime-boost malaria vaccine